Pulmonx Corporation (LUNG)

Pulmonx Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-60.84	-58.92	-48.66	-32.23	-20.7
Depreciation & Amortization	4.23	4.01	3.23	1.95	1.2
Share-Based Compensation	22.1	16.45	10.53	3.2	0.36
Other Operating Activities	-3.1	-6.62	-6.48	-3.55	-1.63
Operating Cash Flow	-37.61	-45.08	-41.39	-30.63	-20.77
Capital Expenditures	-0.81	-1.32	-3.67	-0.91	-0.72
Change in Investments	-1.2	-2.91	-42.58	13.61	-13.51
Investing Cash Flow	-2.01	-4.23	-46.26	12.69	-14.23
Share Issuance / Repurchase	1.49	2.56	4.5	204.08	0.52
Debt Issued / Paid	19.91	-0.14	-0.04	32.83	6
Other Financing Activities	-	-	-	-2.08	39.1
Financing Cash Flow	21.4	2.42	4.46	234.83	45.62
Exchange Rate Effect	0.03	0.15	0.11	0.13	0.02
Net Cash Flow	-18.18	-46.74	-83.08	217.03	10.64
Free Cash Flow	-38.42	-46.4	-45.06	-31.54	-21.49
Free Cash Flow Margin	-55.94%	-86.47%	-93.07%	-96.37%	-65.92%
Free Cash Flow Per Share	-1.01	-1.25	-1.25	-3.10	-12.10

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).